Captrust Financial Advisors Has $4.88 Million Position in Boston Scientific Co. (NYSE:BSX)

Captrust Financial Advisors lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 18.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,580 shares of the medical equipment provider's stock after acquiring an additional 8,316 shares during the period. Captrust Financial Advisors' holdings in Boston Scientific were worth $4,875,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Boston Scientific during the 4th quarter valued at $1,762,522,000. Capital World Investors raised its position in Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares during the period. Wellington Management Group LLP lifted its stake in shares of Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after purchasing an additional 3,344,571 shares in the last quarter. Axiom Investors LLC DE boosted its position in shares of Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after buying an additional 2,535,007 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Boston Scientific by 18.0% in the fourth quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock worth $1,303,681,000 after buying an additional 2,221,790 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity

In related news, CFO Daniel J. Brennan sold 15,087 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. This represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president now owns 22,235 shares in the company, valued at $2,269,304.10. This represents a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 300,497 shares of company stock valued at $31,056,815. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Down 0.1%

Boston Scientific stock traded down $0.10 during trading hours on Monday, hitting $102.76. The company had a trading volume of 6,974,224 shares, compared to its average volume of 6,345,598. The firm's fifty day moving average is $98.64 and its 200-day moving average is $96.19. The firm has a market capitalization of $152.02 billion, a P/E ratio of 82.21, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the previous year, the company earned $0.56 earnings per share. The company's revenue was up 20.9% compared to the same quarter last year. On average, research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BSX. BTIG Research reaffirmed a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Barclays lifted their price objective on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC increased their target price on Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Finally, Citigroup raised their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Buy" and an average price target of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.